Serometrix - Predictive Drug Discovery

	*Redeveloping Pipelines from First Principles*

	Serometrix is leveraging its proprietary Peptimer™ Discovery Platform to help solve industry pipeline challenges by developing a solid understanding of induced fit interface biochemistry. This product based development strategy is providing complex solutions to previously intractable targets of high commercial value. These solutions yield families of compounds with strong IP that are partnered at an early stage for collaborative development.

	PRIMARY AREAS of THERAPEUTIC INTEREST
	Our developing pipeline is currently focused on oncology, cardiovascular, and infectious disease. Our lead program selectively targets the interaction of PCSK9 with LDLR, which is an important target for control of blood cholesterol levels. In the area of Hormone Refractory Prostate Cancer (HRPC) our program is focused on inhibitors of AR cofactor recruitment. Our platform is well positioned to provide value in the following therapeutic areas:
	Oncology Cardiovascular Metabolic CNS Infectious Disease


	PIPELINE OVERVIEW
	SX-PCK9 is a novel family of antagonists for the PCSK9 interaction with LDLR for the potential treatment of hypercholesterolemia. Initial in vitro assays have demonstrated specific antagonist activity against published interaction sites. The project has also identified several unpublished interactions. The program is now iteratively testing synthetic mimetics to enhance activity and understanding at these induced fit interfaces. SX-ARPC is a novel family of compounds that have demonstrated an in vitro ability to down regulate the AR pathway by antagonizing the androgen receptor outside of the ligand binding domain. Optimized versions of these compounds have potential as a novel therapeutics for Prostate Cancer. SX-RDS1 is a novel set of DNA Repair Inhibitors discovered to enhance the effectiveness of radiation therapy in a non-toxic manner. These compounds have been designed to dramatically reduce the frequency and dose of radiation therapy through a unique mechanism of action which gently disables cellular DNA repair mechanisms without interfering with p53 pathways. SX-HIV1 is a family of retroviral integrase inhibitors designed to prohibit the multimerization of the highly conserved integrase enzyme used by many human retroviruses including HIV. This multimerization process is critical to the integration of viral genetic material with the DNA of the infected host cell.
	CONCEPT PHASE PROJECTS
	We have a number of additional internal programs which meet certain scientific and commercial criteria, and for which we have exciting results from our Peptimer™ Discovery Platform. We continue to simulate these interfaces to develop a solid understanding of the precise nature of the critical induced fit interactions. Once completed, these Conceptual Projects will enter pipeline development to further the scope of our protein interaction classes relevant to commercially relevant disease targets. SX-GLP1 is a family of agonist compounds targeting the GLP-1 for the potential treatment of Type II Diabetes. SX-AZD1 is a novel set of compounds targeting proprietary targets that interact with APOE4 for the potential treatment of Alzheimer's Disease (AD). SX-MTR1 is a novel family of compounds targeting the mTOR complex for the treatment of bladder cancer.